In clinical trials and meta-analyses thereof3–7, the complementary effects of GLP1-RA (regulating post-prandial glycemia) and basal insulin (regulating post-absorptive and fasting glycemia) have translated clinically into this combination yielding an ideal therapeutic trifecta – namely, robust glucose-lowering coupled with mitigation of the typical insulin-associated risks of hypoglycemia and weight gain5. The gene discussed is INS; the disease is Hypoglycemia.